Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats

Neuroscience Letters

Volumn 499, Issue 2, 2011, Pages 74-79

  Wang, Ying ^a   Yang, Feng ^a   Liu, Yang Feng ^a   Gao, Fei ^a   Jiang, Wen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acetylsalicylic acid; Chronic unpredictable mild stress; Cyclooxygenase 2; Fluoxetine; Prostaglandin E2; Treatment resistant depression

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; FLUOXETINE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; HIPPOCAMPUS; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ASPIRIN; DEPRESSION; DRUG THERAPY, COMBINATION; FLUOXETINE; HIPPOCAMPUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 79959380712     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.05.035     Document Type: Article

References (34)

1. Almeida O.P., Alfonso H., Jamrozik K., Hankey G.J., Flicker L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J. Am. Geriatr. Soc. 2010, 58:990-992.
2. Benedetti F., Lucca A., Brambilla F., Colombo C., Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1167-1170.
3. Bergstrom A., Jayatissa M.N., Thykjaer T., Wiborg O. Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study. J. Mol. Neurosci. 2007, 33:201-215.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
5. Bodnoff S.R., Suranyi-Cadotte B., Aitken D.H., Quirion R., Meaney M.J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 1988, 95:298-302.
6. Bosetti F., Rintala J., Seemann R., Rosenberger T.A., Contreras M.A., Rapoport S.I., Chang M.C. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry 2002, 7:845-850.
7. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 2006, 21:219-225.
8. Chapman D.P., Perry G.S. Depression as a major component of public health for older adults. Prev. Chronic Dis. 2008, 5:A22.
9. Conley R.K., Hutson P.H. Effects of acute and chronic treatment with fluoxetine on stress-induced hyperthermia in telemetered rats and mice. Eur. J. Pharmacol. 2007, 564:138-145.
10. Conwell Y., Brent D. Suicide and aging. I. Patterns of psychiatric diagnosis. Int. Psychogeriatr. 1995, 7:149-164.
11. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
12. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
13. Kochanek K.D., Murphy S.L., Anderson R.N., Scott C. Deaths: final data for 2002. Natl. Vital Stat. Rep. 2004, 53:1-115.
14. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
15. Le Poul E., Lima L., Laporte A.M., Even C., Doucet E., Fattaccini C.M., Laaris N., Hamon M., Lanfumey L. Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine. Encephale 1995, 21:123-132.
16. Lieb J. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors. Int. J. Immunopharmacol. 1983, 5:353-357.
17. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
18. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
19. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 2006, 21:227-231.
20. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
21. Muller N, Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
22. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
23. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
24. Petersen T., Gordon J.A., Kant A., Fava M., Rosenbaum J.F., Nierenberg A.A. Treatment resistant depression and axis I co-morbidity. Psychol. Med. 2001, 31:1223-1229.
25. Porsolt R.D.B., Jalfre A.M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
26. Rapoport S.I., Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch. Gen. Psychiatry 2002, 59:592-596.
27. Romero S.C., Dela Rosa K.M., Linz P.E. Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. South. Med. J. 2008, 101:725-729.
28. Samson R. Commentary. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Perspect. Vasc. Surg. Endovasc. Ther. 2005, 17:66-67.
29. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196:1025-1037.
30. Sluzewska A., Sobieska M., Rybakowski J.K. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997, 35:123-127.
31. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
32. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
33. Weissman M.M., Bland R.C., Canino G.J., Greenwald S., Hwu H.G., Joyce P.R., Karam E.G., Lee C.K., Lellouch J., Lepine J.P., Newman S.C., Rubio-Stipec M., Wells J.E., Wickramaratne P.J., Wittchen H.U., Yeh E.K. Prevalence of suicide ideation and suicide attempts in nine countries. Psychol. Med. 1999, 29:9-17.
34. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.